Show simple item record

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer.

dc.contributor.authorWu, MY
dc.contributor.authorShepherd, STC
dc.contributor.authorFendler, A
dc.contributor.authorCarr, EJ
dc.contributor.authorAu, L
dc.contributor.authorHarvey, R
dc.contributor.authorDowgier, G
dc.contributor.authorHobbs, A
dc.contributor.authorHerman, LS
dc.contributor.authorRagno, M
dc.contributor.authorAdams, L
dc.contributor.authorSchmitt, AM
dc.contributor.authorTippu, Z
dc.contributor.authorShum, B
dc.contributor.authorFarag, S
dc.contributor.authorRogiers, A
dc.contributor.authorO'Reilly, N
dc.contributor.authorBawumia, P
dc.contributor.authorSmith, C
dc.contributor.authorCarlyle, E
dc.contributor.authorEdmonds, K
dc.contributor.authorDel Rosario, L
dc.contributor.authorLingard, K
dc.contributor.authorMangwende, M
dc.contributor.authorHolt, L
dc.contributor.authorAhmod, H
dc.contributor.authorKorteweg, J
dc.contributor.authorFoley, T
dc.contributor.authorBarber, T
dc.contributor.authorHepworth, S
dc.contributor.authorEmslie-Henry, A
dc.contributor.authorCaulfield-Lynch, N
dc.contributor.authorByrne, F
dc.contributor.authorDeng, D
dc.contributor.authorWilliams, B
dc.contributor.authorBrown, M
dc.contributor.authorCaidan, S
dc.contributor.authorGavrielides, M
dc.contributor.authorMacRae, JI
dc.contributor.authorKelly, G
dc.contributor.authorPeat, K
dc.contributor.authorKelly, D
dc.contributor.authorMurra, A
dc.contributor.authorKelly, K
dc.contributor.authorO'Flaherty, M
dc.contributor.authorPopat, S
dc.contributor.authorYousaf, N
dc.contributor.authorJhanji, S
dc.contributor.authorTatham, K
dc.contributor.authorCunningham, D
dc.contributor.authorVan As, N
dc.contributor.authorYoung, K
dc.contributor.authorFurness, AJS
dc.contributor.authorPickering, L
dc.contributor.authorBeale, R
dc.contributor.authorSwanton, C
dc.contributor.authorGandhi, S
dc.contributor.authorGamblin, S
dc.contributor.authorBauer, DLV
dc.contributor.authorKassiotis, G
dc.contributor.authorHowell, M
dc.contributor.authorWalker, S
dc.contributor.authorNicholson, E
dc.contributor.authorLarkin, J
dc.contributor.authorWall, EC
dc.contributor.authorTurajlic, S
dc.contributor.authorCAPTURE consortium,
dc.coverage.spatialUnited States
dc.date.accessioned2023-07-07T11:16:15Z
dc.date.available2023-07-07T11:16:15Z
dc.date.issued2023-05-08
dc.identifierS1535-6108(23)00131-9
dc.identifier.citationCancer Cell, 2023, 41 (5), pp. 821 - 823
dc.identifier.issn1535-6108
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5882
dc.identifier.eissn1878-3686
dc.identifier.eissn1878-3686
dc.identifier.doi10.1016/j.ccell.2023.04.005
dc.description.abstractWu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants.
dc.formatPrint-Electronic
dc.format.extent821 - 823
dc.languageeng
dc.language.isoeng
dc.publisherCELL PRESS
dc.relation.ispartofCancer Cell
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectHematologic Neoplasms
dc.subjectNeoplasms
dc.titleSotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer.
dc.typeJournal Article
dcterms.dateAccepted2023-04-06
dc.date.updated2023-07-07T11:15:40Z
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1016/j.ccell.2023.04.005
rioxxterms.licenseref.startdate2023-05-08
rioxxterms.typeJournal Article/Review
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/37116490
pubs.issue5
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy/Stereotactic and Precision Body Radiotherapy (hon.)
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/18/19 Starting Cohort
pubs.publication-statusPublished
pubs.publisher-urlhttp://dx.doi.org/10.1016/j.ccell.2023.04.005
pubs.volume41
icr.researchteamMelanoma & Kidney Cancer
icr.researchteamMedicine (RMH)
dc.contributor.icrauthorShepherd, Scott
dc.contributor.icrauthorShum, Ben
dc.contributor.icrauthorFurness, Andrew
icr.provenanceDeposited by Mr Arek Surman (impersonating Dr Doug Brand) on 2023-07-07. Deposit type is initial. No. of files: 1. Files: Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer.pdf


Files in this item

Thumbnail
Name:
Sotrovimab restores neutralization ...
Size:
338.0Kb
Format:
PDF
View/Open

This item appears in the following collection(s)

Show simple item record